Allogeneic Transplantation
Myelodysplastic Syndrome Trials (MDS & CMML)
COMIRB: 17-2215
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes
Principal Investigator: Dan Pollyea
Eligibility: Ages ≥ 18 years; high grade MDS or CMML-1 with greater than 5% bone marrow blasts or CMML-2; ECOG of ≤2
COMIRB: 22-0130
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants with Myelofibrosis and Other Advanced Myeloid Neoplasms
PI: Brandon McMahon
Eligibility: Ages ≥ 18; Relapsed or refractory MF, MDS, or MDS/MPN (Part 1); ECOG of ≤2
COMIRB: 20-1388
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
PI: Dan Pollyea
Eligibility: Ages ≥ 18 years; Relapsed or refractory CMML and has failed treatment with available therapies known to be active for CMML; Hypomethylating-agent naive CMML regardless of LILRB4 expression levels; ECOG of ≤ 2
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.